Keith Kendall Net Worth

The estimated Net Worth of Keith J Kendall is at least $6.05 Milión dollars as of 30 June 2020. Mr. Kendall owns over 333 units of Aquestive Therapeutics Inc stock worth over $3,164,520 and over the last 6 years he sold AQST stock worth over $255,500. In addition, he makes $2,628,580 as President, Chief Executive Officer a Director at Aquestive Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kendall AQST stock SEC Form 4 insiders trading

Keith has made over 16 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 333 units of AQST stock worth $1,648 on 30 June 2020.

The largest trade he's ever made was selling 50,000 units of Aquestive Therapeutics Inc stock on 4 June 2020 worth over $255,500. On average, Keith trades about 5,584 units every 21 days since 2018. As of 30 June 2020 he still owns at least 639,297 units of Aquestive Therapeutics Inc stock.

You can see the complete history of Mr. Kendall stock trades at the bottom of the page.

Keith Kendall biography

Keith J. Kendall serves as President, Chief Executive Officer, Director of the Company. Keith J. Kendall has served as our Chief Executive Officer and President and as a member of our Board since November 2014, after having served as our President and Chief Operating Officer from November 2011 to November 2014 and as our Executive Vice President and Chief Financial Officer from 2006 to 2011. From 1999 to 2006, Mr. Kendall served in various business leadership positions for Hewlett Packard Financial Services, most recently as Vice President and Managing Director of the Americas. From 1985 to 1998, Mr. Kendall held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall served on the board of directors of Midatech Pharma Plc (Nasdaq: MTP) from January 2010 to December 2014. Mr. Kendall holds a B.S. from St. John’s University and an M.B.A from Pace University. Our Board believes that Mr. Kendall’s perspective and experience as our Chief Executive Officer, as well as his depth of operating and senior management experience in our industry, qualifies him to serve on our Board of Directors.

What is the salary of Keith Kendall?

As the President, Chief Executive Officer a Director of Aquestive Therapeutics Inc, the total compensation of Keith Kendall at Aquestive Therapeutics Inc is $2,628,580. There are 1 executives at Aquestive Therapeutics Inc getting paid more, with A. Mark Schobel having the highest compensation of $7,575,660.

How old is Keith Kendall?

Keith Kendall is 62, he's been the President, Chief Executive Officer a Director of Aquestive Therapeutics Inc since 2014. There are 7 older and 11 younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.

What's Keith Kendall's mailing address?

Keith's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.

Insiders trading at Aquestive Therapeutics Inc

Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker a Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.

What does Aquestive Therapeutics Inc do?

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Complete history of Mr. Kendall stock trades at Aquestive Therapeutics Inc

Aquestive Therapeutics Inc executives and stock owners

Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include:

• A. Mark Schobel,
  Chief Innovation and Technology Officer
• Keith Kendall,
  President, Chief Executive Officer, Director
• Daniel Barber,
  Chief Operating Officer, Senior Vice President
• John Maxwell,
  Senior Vice President, Chief Financial Officer
• Keith J. Kendall,
  CEO, Pres & Director
• Daniel Barber,
  Sr. VP & COO
• Santo Costa,
  Independent Chairman of the Board
• James Scibetta,
  Independent Director
• Douglas Bratton,
  Independent Director
• Nancy Lurker,
  Independent Director
• Gregory Brown,
  Independent Director
• John Cochran,
  Vice Chairman of the Board
• Gary Slatko,
  Senior Vice President, Chief Medical Officer
• Kenneth Marshall,
  Senior Vice President - Chief Commercial Officer
• Peter Boyd,
  Senior Vice President - Business Process and Information Technology
• Theresa Wood,
  Senior Vice President - Human Resources and Organizational Development
• Lori Braender,
  Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
• Dr. Gary H. Slatko M.D., MBA,
  Sr. VP & Chief Medical Officer
• Kenneth W. Marshall,
  Sr. VP & Chief Commercial Officer
• Peter E. Boyd,
  Sr. VP of Bus. Process & Information Technology
• Dr. Eric Dadey Ph.D.,
  Sr. Vice-Pres of R&D
• Theresa Wood,
  Sr. VP of HR & Organizational Devel.
• Lori J. Braender Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Alexander Mark Schobel,
  Chief Innovation & Technology Officer
• A. Ernest Toth Jr.,
  Sr. VP & CFO
• Timothy E Morris,
  
• Ken W. Marshall,
  SVP, Chief Commercial Officer
• Marco Taglietti,
  
• Julie Krop,
  
• Douglas K Monoline Partners...,
  
• Cassie Jung,
  SVP, Operations
• Douglas K Mono Line Partner...,
  
• Kenneth Truitt,
  Chief Medical Officer
• A Ernest Jr Toth,
  SVP, Chief Financial Officer
• Carl N Kraus,
  Chief Medical Officer
• Stephen Wargacki,
  Chief Science Officer
• Abigail L. Jenkins,
  
• Sherry Korczynski,
  SVP Sales and Marketing